IP Library Granted Patent US 9,593,310
Granted Patent B2
US 9,593,310 · App. 14/840,297 · Granted Mar 14, 2017

Differentiation of human embryonic stem cells

Inventor: Jean Xu (Raritan, NJ)
Assignee: Janssen Biotech, Inc.
C12N5/0676C12N2501/117C12N2501/16C12N2501/41C12N2501/415C12N2501/70C12N2506/02C12N2533/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,593,310
App. No.
14/840,297
Granted
Mar 14, 2017
Kind
B2
Abstract

The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce cells expressing markers characteristic of the pancreatic endocrine lineage that co-express NKX6.1 and insulin and minimal amounts of glucagon.

Claims (8)

1. An in vitro culture of a population of cells that co-express NKX6.1 and insulin in a culture medium supplemented with (2S,5S)-(E,E)-8-(5-(4-(Trifluoromethyl)phenyl)-2,4-pentadienoylamino) benzolactam, wherein less than 10% of the cells in the population express glucagon, and wherein the population of cells is obtained by a step-wise differentiation protocol which comprises culturing pancreatic endoderm cells in the medium supplemented with (2S,5S)-(E,E)-8-(5-(4-(Trifluoromethyl)phenyl)-2,4-pentadienoylamino) benzolactam.

2. The in vitro culture of claim 1 , wherein at least 30% of the cells express NKX6.1.

3. The in vitro culture of claim 1 , wherein at least 40% of the cells express NKX.6.1.

4. The in vitro culture of claim 1 , wherein at least 50% of the cells express NKX6.1.

5. The in vitro culture of claim 1 , wherein at least 60% of the cells express NKX6.1.

6. The in vitro culture of claim 1 , wherein at least 5% of the cells express insulin.

7. The in vitro culture of claim 1 , wherein the medium is supplemented with one or more of noggin or a TGFβ receptor signaling inhibitor.

8. The in vitro culture of claim 7 , wherein the TGFβ receptor signaling inhibitor is an inhibitor of ALK5.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 15, 2023
From: XU, JEAN
To: CENTOCOR ORTHO BIOTECH, INC.
Reel/Frame 065222/0865 →
CHANGE OF NAME Recorded Oct 15, 2023
From: CENTOCOR ORTHO BIOTECH INC.
To: JANSSEN BIOTECH, INC.
Reel/Frame 065238/0846 →
Continuity (3)
Continuation 12970330 · Dec 16, 2010
Provisional Application 61289671 · Dec 23, 2009
Related Publication 20160032250A1 · Feb 4, 2016